Pretreatment serum albumin-to-alkaline phosphatase ratio is an independent prognosticator of survival in patients with metastatic gastric cancer

Table 1 Baseline patient information and characteristics

Characteristics	Before propensity matching			After propensity matching
	AAPR ≤ 0.48 (n = 86)	AAPR > 0.48 (n = 105)	P value	AAPR ≤ 0.48 (n = 58)	AAPR > 0.48 (n = 58)	P value
Gender						0.265
Male	56	49	0.011	32	26
Female	30	56		26	32
Age
≤ 60	59	72	0.996	39	40	0.842
> 60	27	33		19	18
Smoking status
No	61	85	0.018	44	48	0.359
Yes	25	20		14	10
Number of involved sites
One	41	68	0.018	30	24	0.264
Multiple	45	37		28	34
Liver metastasis
No	48	86	0.000	44	44	1.000
Yes	38	19		14	14
Bone metastasis
No	70	97	0.023	50	50	1.00
Yes	16	8		8	8
Pathology
High differentiated	3	1	0.201	1	0	0.334
Moderately differentiated	3	4		3	2
Poorly differentiated	31	46		17	25
Signet ring cell	13	25		9	13
Others	2	3		1	1
Unknown	34	26		27	17
Treatment regimens
Combination chemotherapy	63	83	0.520	45	44	0.378
Fluorouracil or taxane alone	11	7		7	3
Radiotherapy	1	2		1	2
Best supportive care	11	13		5	9

AAPR: Albumin-to-alkaline phosphatase ratio.

Table 2 Univariate and multivariate analyses of prognostic factors for overall survival for all patients

Variables	Univariate analyses		Multivariate analyses
	HR (95%CI)	P value	HR (95%CI)	P value
Gender (male vs female)	0.705 (0.510-0.975)	0.035	0.746 (0.508-1.094)	0.133
Age (> 60 vs ≤ 60)	1.125 (0.794-1.594)	0.509	0.808 (0.541-1.207)	0.298
Smoking status (Yes vs No)	1.451 (0.970-2.173)	0.070	1.364 (0.851-2.188)	0.197
Number of involved sites (multiple vs one)	1.748 (1.264-2.417)	0.001	1.425 (1.018-1.997)	0.038
Liver metastasis (Yes vs No)	0.950 (0.674-1.339)	0.731	0.758 (0.511-1.124)	0.167
Bone metastasis (Yes vs No)	1.319 (0.822-2.115)	0.251	1.395 (0.843-2.307)	0.195
Treatment regimens (combination chemotherapy vs others)	0.334 (0.232-0.480)	0.000	0.269 (0.175-0.411)	0.000
AAPR (> 0.48 vs ≤ 0.48)	0.536 (0.385-0.745)	0.000	0.476 (0.328-0.691)	0.000

HR: Hazard ratio; CI: Confidence interval; AAPR: Albumin-to-alkaline phosphatase ratio.

Table 3 Univariate and multivariate analyses of prognostic factors for progression-free survival for all patients

Variables	Univariate analyses		Multivariate analyses
	HR (95%CI)	P value	HR (95%CI)	P value
Gender (male vs female)	0.759 (0.554-1.041)	0.087	0.772 (0.529-1.126)	0.179
Age (> 60 vs ≤ 60)	1.162 (0.830-1.626)	0.382	0.955 (0.654-1.395)	0.813
Smoking status (Yes vs No)	0.805 (0.550-1.177)	0.262	1.227 (0.781-1.927)	0.375
Number of involved sites (multiple vs one)	1.484 (1.083-2.034)	0.014	1.223 (0.880-1.701)	0.231
Liver metastasis (Yes vs No)	0.950 (0.674-1.339)	0.770	0.737 (0.506-1.073)	0.112
Bone metastasis (Yes vs No)	1.219 (0.762-1.951)	0.409	1.232 (0.754-2.011)	0.405
Treatment regimens (combination chemotherapy vs others)	0.448 (0.313-0.639)	0.000	0.398 (0.263-0.594)	0.000
AAPR (> 0.48 vs ≤ 0.48)	0.611 (0.446-0.837)	0.002	0.527 (0.370-0.751)	0.000

HR: Hazard ratio; CI: Confidence interval; AAPR: Albumin-to-alkaline phosphatase ratio.